バイオ医薬品受託製造市場規模、シェア、動向分析レポート：供給元別、サービス別、薬剤タイプ別、タイプ別、事業規模別、治療領域別、地域別、セグメント予測、2025年～2030年

バイオ医薬品受託製造市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のバイオ医薬品受託製造市場規模は2030年までに758億米ドルに達し、2025年から2030年までのCAGRは11.1%で拡大すると推定されています。

バイオ医薬品パイプラインの成長と適切な製造能力の不足は、高分子メーカーと受託製造機関（CMO）の提携を促進する2つの重要な要因です。受託製造企業は、規制基準や新サービスに関する企業の要求に応えるため、サービス・ポートフォリオの拡充に取り組んでいます。しかし、パンデミックは、予算や資源が「COVID製品」に振り向けられ、他の治療領域で開発中の他の生物製剤プロジェクトが犠牲になるなど、マイナスの影響も及ぼしています。

生物製剤とバイオシミラーの生産における企業のCMOへの依存度は、CMOが採用する変化の結果として、予測期間中に上昇すると予想されます。このことは、企業とCMOとの協業への投資の増加や、サービス・ポートフォリオの拡大に向けた継続的な取り組みからも明らかです。バイオ医薬品のサプライチェーンは強固であり、コロナウイルスの大流行中も世界的にほとんど影響を受けなかった。また、バイオ医薬品の受託製造業者は、COVID-19ワクチンや治療薬に関する需要の増加を観察しています。このように、将来は市場にとって多くのチャンスがあります。例えば、2020年にアストラゼネカとオックスフォード・バイオメディカは、アストラゼネカのCOVID-19ワクチン候補であるAZD1222の製造に関する1年間の臨床・商業供給契約を締結しました。

市場の今後の成長は、バイオ医薬品業界、バイオプロセス業界、受託サービス業界が提供する有望な機会に大きく左右されます。充填・仕上げサービスの拡大とライフサイエンス分野へのベンチャーキャピタル投資の堅調化は、市場を牽引すると予想される2つの重要な機会です。例えば、2019年にShanghai HaiHe Biopharma Co.Ltd.は、アウトソーシングパートナーであるZhejiang Jiuzhou Pharmaceutical Co., Ltd.とともに活用する大規模な抗がん剤ポートフォリオのために、ベンチャーキャピタルとして1億4,660万米ドルを調達しました。

バイオ医薬品受託製造市場レポートハイライト

• 哺乳類ベースのバイオ医薬品受託製造は、生物製剤開発における哺乳類発現系の高い普及率により、2024年には約57.1%の最大市場シェアを獲得。
• プロセス開拓サービスは、特に下流プロセスにおける高い設備投資により、2024年の世界市場で最大の売上シェアを占めました。
• バイオ医薬品受託製造は、生物製剤製造の需要が高いことから、同セグメントを支配しました。しかし、バイオシミラー医薬品の開発にはコスト削減のメリットがあるため、バイオシミラー医薬品の分野が予測期間中に最も速いCAGRを記録すると予想されます。
• 米国には生物製剤開発のための効果的な規制枠組みが存在するため、2024年の北米市場のシェアは34.3%と大きいです。
• アジア太平洋地域のバイオ医薬品受託製造市場は有利なペースで成長しており、インドや中国などの新興経済諸国が競争を維持するための開発を取り入れているため、バイオ医薬品の研究開発・製造において最も急成長している地域となる見込みです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 バイオ医薬品受託製造市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/補助市場見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 製品パイプライン分析
• 価格モデル分析
• 市場分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析

第4章 バイオ医薬品受託製造市場：供給元の推定・動向分析

• セグメントダッシュボード
• 供給元変動分析
• 供給元別、2018年～2030年
• 哺乳類
• 非哺乳類

第5章 バイオ医薬品受託製造市場：サービスの推定・動向分析

• セグメントダッシュボード
• サービス変動分析
• サービス別、2018年～2030年
• プロセス開発
  • 下流処理
  • 上流処理
• 充填および仕上げ作業
• 分析および品質管理研究
• 包装とラベル

第6章 バイオ医薬品受託製造市場：薬剤タイプの推定・動向分析

• セグメントダッシュボード
• 薬物タイプの変動分析
• 薬剤タイプ別、2018年～2030年
• 生物学的製剤
  • モノクローナル抗体
  • 組み換えタンパク質
  • ワクチン
  • アンチセンス、RNAi、分子療法
  • その他
• バイオシミラー

第7章 バイオ医薬品受託製造市場：タイプの推定・動向分析

• セグメントダッシュボード
• タイプ変動分析
• タイプ別、2018年～2030年
• 薬物成分
• 完成した医薬品

第8章 バイオ医薬品受託製造市場：事業規模の推定・動向分析

• セグメントダッシュボード
• 事業規模変動分析
• 事業規模別、2018年～2030年
• 臨床
• 商用

第9章 バイオ医薬品受託製造市場：治療領域の推定・動向分析

• セグメントダッシュボード
• 治療領域の変動分析
• 治療領域別、2018-2030年
• 腫瘍
• 自己免疫疾患
• 感染症
• 心血管疾患
• 代謝性疾患
• 神経学
• その他

第10章 バイオ医薬品受託製造市場：地域の推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東およびアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ
  • クウェート

第11章 競合情勢

• 企業分類
  • マーケットリーダー
  • 新興企業
• 企業市況分析、2024年（企業ヒートマップ分析）
• 企業プロファイル
  • Boehringer Ingelheim GmbH
  • Lonza
  • Inno Biologics Sdn Bhd
  • Rentschler Biotechnologies GmbH
  • JRS PHARMA
  • AGC Biologics
  • ProBioGen
  • FUJIFILM Diosynth Biotechnologies USA, Inc.
  • Toyobo Co. Ltd.
  • Samsung Biologics
  • Thermo Fisher Scientific, Inc.
  • Binex Co., Ltd.
  • WuXi Biologics
  • AbbVie, Inc.
  • ADMA Biologics, Inc.
  • Catalent, Inc
  • Cambrex Corporation
  • Pfizer Inc.
  • Siegfried Holding AG

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 4 Global Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 5 Global Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 6 Global Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 7 Global Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 8 Global Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 9 Global Biopharmaceutical Contract Manufacturing, by Region, 2018 - 2030 (USD Million)
• Table 10 North America Biopharmaceutical Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
• Table 11 North America Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 12 North America Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 13 North America Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 14 North America Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 15 North America Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 16 North America Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 17 U.S. Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 18 U.S. Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 19 U.S. Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 20 U.S. Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 21 U.S. Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 22 U.S. Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 23 Canada Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 24 Canada Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 25 Canada Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 26 Canada Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 27 Canada Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 28 Canada Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 29 Mexico Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 30 Mexico Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 31 Mexico Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 32 Mexico Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 33 Mexico Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 34 Mexico Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 35 Europe Biopharmaceutical Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
• Table 36 Europe Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 37 Europe Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 38 Europe Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 39 Europe Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 40 Europe Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 41 Europe Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 42 Germany Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 43 Germany Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 44 Germany Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 45 Germany Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 46 Germany Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 47 Germany Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 48 UK Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 49 UK Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 50 UK Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 51 UK Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 52 UK Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 53 UK Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 54 France Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 55 France Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 56 France Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 57 France Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 58 France Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 59 France Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 60 Italy Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 61 Italy Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 62 Italy Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 63 Italy Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 64 Italy Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 65 Italy Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 66 Spain Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 67 Spain Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 68 Spain Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 69 Spain Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 70 Spain Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 71 Spain Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 72 Denmark Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 73 Denmark Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 74 Denmark Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 75 Denmark Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 76 Denmark Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 77 Denmark Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 78 Sweden Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 79 Sweden Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 80 Sweden Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 81 Sweden Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 82 Sweden Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 83 Sweden Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 84 Norway Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 85 Norway Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 86 Norway Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 87 Norway Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 88 Norway Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 89 Norway Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 90 Asia Pacific Biopharmaceutical Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
• Table 91 Asia Pacific Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 92 Asia Pacific Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 93 Asia Pacific Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 94 Asia Pacific Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 95 Asia Pacific Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 96 Asia Pacific Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 97 China Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 98 China Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 99 China Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 100 China Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 101 China Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 102 China Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 103 Japan Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 104 Japan Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 105 Japan Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 106 Japan Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 107 Japan Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 108 Japan Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 109 India Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 110 India Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 111 India Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 112 India Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 113 India Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 114 India Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 115 South Korea Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 116 South Korea Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 117 South Korea Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 118 South Korea Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 119 South Korea Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 120 South Korea Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 121 Australia Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 122 Australia Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 123 Australia Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 124 Australia Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 125 Australia Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 126 Australia Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 127 Thailand Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 128 Thailand Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 129 Thailand Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 130 Thailand Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 131 Thailand Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 132 Thailand Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 133 Latin America Biopharmaceutical Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
• Table 134 Latin America Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 135 Latin America Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 136 Latin America Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 137 Latin America Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 138 Latin America Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 139 Latin America Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 140 Brazil Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 141 Brazil Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 142 Brazil Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 143 Brazil Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 144 Brazil Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 145 Brazil Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 146 Argentina Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 147 Argentina Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 148 Argentina Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 149 Argentina Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 150 Argentina Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 151 Argentina Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 152 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
• Table 153 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 154 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 155 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 156 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 157 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 158 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 159 South Africa Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 160 South Africa Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 161 South Africa Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 162 South Africa Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 163 South Africa Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 164 South Africa Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 165 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 166 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 167 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 168 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 169 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 170 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 171 UAE Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 172 UAE Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 173 UAE Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 174 UAE Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 175 UAE Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 176 UAE Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 177 Kuwait Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
• Table 178 Kuwait Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
• Table 179 Kuwait Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
• Table 180 Kuwait Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
• Table 181 Kuwait Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
• Table 182 Kuwait Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Biopharmaceutical Contract Manufacturing, Market Segmentation
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Market Dynamics
• Fig. 8 Market Driver Analysis (Current & Future Impact)
• Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 10 Porter's Five Forces Analysis
• Fig. 11 PESTEL Analysis, By SWOT Analysis
• Fig. 12 Regional Marketplace: Key Takeaways
• Fig. 13 Global Biopharmaceutical Contract Manufacturing, for Mammalian, 2018 - 2030 (USD Million)
• Fig. 14 Global Biopharmaceutical Contract Manufacturing, for Non-mammalian, 2018 - 2030 (USD Million)
• Fig. 15 Global Biopharmaceutical Contract Manufacturing, for Process Development, 2018 - 2030 (USD Million)
• Fig. 16 Global Biopharmaceutical Contract Manufacturing, for Downstream, 2018 - 2030 (USD Million)
• Fig. 17 Global Biopharmaceutical Contract Manufacturing, for Upstream, 2018 - 2030 (USD Million)
• Fig. 18 Global Biopharmaceutical Contract Manufacturing, for Fill & Finish Operations, 2018 - 2030 (USD Million)
• Fig. 19 Global Biopharmaceutical Contract Manufacturing, for Analytical & QC Studies, 2018 - 2030 (USD Million)
• Fig. 20 Global Biopharmaceutical Contract Manufacturing, for Packaging & Labelling & Labelling, 2018 - 2030 (USD Million)
• Fig. 21 Global Biopharmaceutical Contract Manufacturing, for Others, 2018 - 2030 (USD Million)
• Fig. 22 Global Biopharmaceutical Contract Manufacturing, for Biologics, 2018 - 2030 (USD Million)
• Fig. 23 Global Biopharmaceutical Contract Manufacturing, for Monoclonal Antibodies (mAbs), 2018 - 2030 (USD Million)
• Fig. 24 Global Biopharmaceutical Contract Manufacturing, for Recombinant Proteins, 2018 - 2030 (USD Million)
• Fig. 25 Global Biopharmaceutical Contract Manufacturing, for Vaccines, 2018 - 2030 (USD Million)
• Fig. 26 Global Biopharmaceutical Contract Manufacturing, for Antisense, RNAi, & Molecular Therapy, 2018 - 2030 (USD Million)
• Fig. 27 Global Biopharmaceutical Contract Manufacturing, for Others, 2018 - 2030 (USD Million)
• Fig. 28 Global Biopharmaceutical Contract Manufacturing, for Biosimilars, 2018 - 2030 (USD Million)
• Fig. 29 Global Biopharmaceutical Contract Manufacturing, for Drug Substance, 2018 - 2030 (USD Million)
• Fig. 30 Global Biopharmaceutical Contract Manufacturing, for Finished Drug Product, 2018 - 2030 (USD Million)
• Fig. 31 Global Biopharmaceutical Contract Manufacturing, for Clinical, 2018 - 2030 (USD Million)
• Fig. 32 Global Biopharmaceutical Contract Manufacturing, for Commercial, 2018 - 2030 (USD Million)
• Fig. 33 Global Biopharmaceutical Contract Manufacturing, for Oncology, 2018 - 2030 (USD Million)
• Fig. 34 Global Biopharmaceutical Contract Manufacturing, for Autoimmune Diseases, 2018 - 2030 (USD Million)
• Fig. 35 Global Biopharmaceutical Contract Manufacturing, for Infectious Diseases, 2018 - 2030 (USD Million)
• Fig. 36 Global Biopharmaceutical Contract Manufacturing, for Cardiovascular Diseases, 2018 - 2030 (USD Million)
• Fig. 37 Global Biopharmaceutical Contract Manufacturing, for Metabolic Diseases, 2018 - 2030 (USD Million)
• Fig. 38 Global Biopharmaceutical Contract Manufacturing, for Neurology, 2018 - 2030 (USD Million)
• Fig. 39 Global Biopharmaceutical Contract Manufacturing, for Others, 2018 - 2030 (USD Million)
• Fig. 40 Regional Outlook, 2024 & 2030
• Fig. 41 North America Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 42 U.S. Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Canada Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Mexico Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Europe Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 46 UK Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Germany Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 48 France Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Italy Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Spain Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Denmark Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Sweden Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Norway Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Asia Pacific Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 55 India Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 56 China Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Japan Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 58 South Korea Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Australia Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Thailand Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Latin America Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Brazil Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Argentina Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Middle East & Africa Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 65 South Africa Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Saudi Arabia Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 67 UAE Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Kuwait Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Biopharmaceuticals Contract Manufacturing Market Growth & Trends:

The global biopharmaceuticals contract manufacturing market size is estimated to reach USD 75.80 billion by 2030, expanding at a CAGR of 11.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet the companies' demands with respect to regulatory standards and new services. The pandemic has, however, also had some negative knock-on effects as budgets and resources are diverted to "COVID products" at the expense of other biologics projects in development for other therapeutic areas.

The reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise during the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio. The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca's COVID-19 vaccine candidate, AZD1222.

The future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

Biopharmaceuticals Contract Manufacturing Market Report Highlights:

• Mammalian-based biopharmaceutical contract manufacturing captured the largest market share about 57.1% in 2024 owing to the high penetration of mammalian expression systems for biologics development
• Process development services held the largest revenue share in the global market in 2024., owing to high capital investment, especially in downstream process
• Biologics contract manufacturing dominated its counterpart segment owing to higher demand for biologics production. However, The biosimilar segment is anticipated to register the fastest CAGR over the forecast period due to cost-saving advantages associated with biosimilars development
• The presence of an effective regulatory framework for biologics development in the U.S. has resulted in a large share of the North America market of 34.3% in 2024
• Asia Pacific biopharmaceuticals contract manufacturing market is growing at a lucrative pace and is expected to emerge as the fastest-growing geographical area for biopharmaceutical R&D and manufacturing owing to developing economies such as India and China incorporating developments to sustain the competition

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceuticals Contract Manufacturing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rise in investment by CMOs for capacity expansion
    • 3.2.1.2. Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals
    • 3.2.1.3. Notable growth of biologics approvals
    • 3.2.1.4. Robust biopharmaceuticals pipeline
    • 3.2.1.5. Cost and time-saving benefits offered by contract services
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Limited outsourcing amongst well-established biopharmaceutical manufacturer
    • 3.2.2.2. Managing Relationships
• 3.3. Product Pipeline Analysis
• 3.4. Pricing Model Analysis
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL Analysis

Chapter 4. Biopharmaceuticals Contract Manufacturing Market: Source Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Source Movement Analysis
• 4.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Source, 2018-2030 (USD Million)
• 4.4. Mammalian
  • 4.4.1. Mammalian Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Non-mammalian
  • 4.5.1. Non-mammalian Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Biopharmaceuticals Contract Manufacturing Market: Service Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Service Movement Analysis
• 5.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Service, 2018-2030 (USD Million)
• 5.4. Process Development
  • 5.4.1. Process Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Downstream Processing
    • 5.4.2.1. Downstream Processing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Upstream Processing
    • 5.4.3.1. Upstream Processing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Fill & Finish Operations
  • 5.5.1. Fill & Finish Operations Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Analytical & QC Studies
  • 5.6.1. Analytical & QC Studies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Packaging & Labelling
  • 5.7.1. Packaging & Labelling Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Biopharmaceuticals Contract Manufacturing Market: Drug Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Drug Type Movement Analysis
• 6.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Drug Type, 2018-2030 (USD Million)
• 6.4. Biologics
  • 6.4.1. Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. Monoclonal Antibodies
    • 6.4.2.1. Monoclonal Antibodies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Recombinant proteins
    • 6.4.3.1. Recombinant Proteins Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Vaccines
    • 6.4.4.1. Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.5. Antisense, RNAi, & Molecular Therapy
    • 6.4.5.1. Antisense, RNAi, & Molecular Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Biosimilar
  • 6.5.1. Biosimilar Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Biopharmaceuticals Contract Manufacturing Market: Type Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Type Movement Analysis
• 7.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Type, 2018-2030 (USD Million)
• 7.4. Drug Substance
  • 7.4.1. Drug Substance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Finished Drug Product
  • 7.5.1. Finished Drug Product Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Biopharmaceuticals Contract Manufacturing Market: Scale of Operation Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Scale of Operation Movement Analysis
• 8.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Scale of Operation, 2018-2030 (USD Million)
• 8.4. Clinical
  • 8.4.1. Clinical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Commercial
  • 8.5.1. Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis

• 9.1. Segment Dashboard
• 9.2. Therapeutic Area Movement Analysis
• 9.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Therapeutic Area, 2018-2030 (USD Million)
• 9.4. Oncology
  • 9.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.5. Autoimmune Diseases
  • 9.5.1. Autoimmune Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.6. Infectious Diseases
  • 9.6.1. Infectious Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.7. Cardiovascular Diseases
  • 9.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.8. Metabolic Diseases
  • 9.8.1. Metabolic Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.9. Neurology
  • 9.9.1. Neurology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.10. Others
  • 9.10.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Biopharmaceuticals Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 10.1. Regional market share analysis, 2024 & 2030
• 10.2. Regional Market Dashboard
• 10.3. North America
  • 10.3.1. North America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.3.2. U.S.
    • 10.3.2.1. Key Country Dynamics
    • 10.3.2.2. Competitive Scenario
    • 10.3.2.3. Regulatory Landscape
    • 10.3.2.4. U.S. Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.3.3. Canada
    • 10.3.3.1. Key Country Dynamics
    • 10.3.3.2. Competitive Scenario
    • 10.3.3.3. Regulatory Landscape
    • 10.3.3.4. Canada Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.3.4. Mexico
    • 10.3.4.1. Key Country Dynamics
    • 10.3.4.2. Competitive Scenario
    • 10.3.4.3. Regulatory Landscape
    • 10.3.4.4. Mexico Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 10.4. Europe
  • 10.4.1. Europe Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.2. U.K.
    • 10.4.2.1. Key Country Dynamics
    • 10.4.2.2. Competitive Scenario
    • 10.4.2.3. Regulatory Landscape
    • 10.4.2.4. U.K. Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.3. Germany
    • 10.4.3.1. Key Country Dynamics
    • 10.4.3.2. Competitive Scenario
    • 10.4.3.3. Regulatory Landscape
    • 10.4.3.4. Germany Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.4. France
    • 10.4.4.1. Key Country Dynamics
    • 10.4.4.2. Competitive Scenario
    • 10.4.4.3. Regulatory Landscape
    • 10.4.4.4. France Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.5. Italy
    • 10.4.5.1. Key Country Dynamics
    • 10.4.5.2. Competitive Scenario
    • 10.4.5.3. Regulatory Landscape
    • 10.4.5.4. Italy Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.6. Spain
    • 10.4.6.1. Key Country Dynamics
    • 10.4.6.2. Competitive Scenario
    • 10.4.6.3. Regulatory Landscape
    • 10.4.6.4. Spain Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.7. Denmark
    • 10.4.7.1. Key Country Dynamics
    • 10.4.7.2. Competitive Scenario
    • 10.4.7.3. Regulatory Landscape
    • 10.4.7.4. Denmark Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.8. Sweden
    • 10.4.8.1. Key Country Dynamics
    • 10.4.8.2. Competitive Scenario
    • 10.4.8.3. Regulatory Landscape
    • 10.4.8.4. Sweden Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.9. Norway
    • 10.4.9.1. Key Country Dynamics
    • 10.4.9.2. Competitive Scenario
    • 10.4.9.3. Regulatory Landscape
    • 10.4.9.4. Norway Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 10.5. Asia Pacific
  • 10.5.1. Asia Pacific Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5.2. China
    • 10.5.2.1. Key Country Dynamics
    • 10.5.2.2. Competitive Scenario
    • 10.5.2.3. Regulatory Landscape
    • 10.5.2.4. China Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5.3. Japan
    • 10.5.3.1. Key Country Dynamics
    • 10.5.3.2. Competitive Scenario
    • 10.5.3.3. Regulatory Landscape
    • 10.5.3.4. Japan Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5.4. India
    • 10.5.4.1. Key Country Dynamics
    • 10.5.4.2. Competitive Scenario
    • 10.5.4.3. Regulatory Landscape
    • 10.5.4.4. India Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5.5. South Korea
    • 10.5.5.1. Key Country Dynamics
    • 10.5.5.2. Competitive Scenario
    • 10.5.5.3. Regulatory Landscape
    • 10.5.5.4. South Korea Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5.6. Australia
    • 10.5.6.1. Key Country Dynamics
    • 10.5.6.2. Competitive Scenario
    • 10.5.6.3. Regulatory Landscape
    • 10.5.6.4. Australia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5.7. Thailand
    • 10.5.7.1. Key Country Dynamics
    • 10.5.7.2. Competitive Scenario
    • 10.5.7.3. Regulatory Landscape
    • 10.5.7.4. Thailand Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 10.6. Latin America
  • 10.6.1. Latin America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.6.2. Brazil
    • 10.6.2.1. Key Country Dynamics
    • 10.6.2.2. Competitive Scenario
    • 10.6.2.3. Regulatory Landscape
    • 10.6.2.4. Brazil Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.6.3. Argentina
    • 10.6.3.1. Key Country Dynamics
    • 10.6.3.2. Competitive Scenario
    • 10.6.3.3. Regulatory Landscape
    • 10.6.3.4. Argentina Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 10.7. Middle East and Africa
  • 10.7.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.7.2. Saudi Arabia
    • 10.7.2.1. Key Country Dynamics
    • 10.7.2.2. Competitive Scenario
    • 10.7.2.3. Regulatory Landscape
    • 10.7.2.4. Saudi Arabia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.7.3. UAE
    • 10.7.3.1. Key Country Dynamics
    • 10.7.3.2. Competitive Scenario
    • 10.7.3.3. Regulatory Landscape
    • 10.7.3.4. UAE Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.7.4. South Africa
    • 10.7.4.1. Key Country Dynamics
    • 10.7.4.2. Competitive Scenario
    • 10.7.4.3. Regulatory Landscape
    • 10.7.4.4. South Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.7.5. Kuwait
    • 10.7.5.1. Key Country Dynamics
    • 10.7.5.2. Competitive Scenario
    • 10.7.5.3. Regulatory Landscape
    • 10.7.5.4. Kuwait Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Company Categorization
  • 11.1.1. Market Leaders
  • 11.1.2. Emerging Players
• 11.2. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
• 11.3. Company Profiles
  • 11.3.1. Boehringer Ingelheim GmbH
    • 11.3.1.1. Participant's Overview
    • 11.3.1.2. Financial Performance
    • 11.3.1.3. Service Benchmarking
    • 11.3.1.4. Strategic Initiatives
  • 11.3.2. Lonza
    • 11.3.2.1. Participant's Overview
    • 11.3.2.2. Financial Performance
    • 11.3.2.3. Service Benchmarking
    • 11.3.2.4. Strategic Initiatives
  • 11.3.3. Inno Biologics Sdn Bhd
    • 11.3.3.1. Participant's Overview
    • 11.3.3.2. Financial Performance
    • 11.3.3.3. Service Benchmarking
    • 11.3.3.4. Strategic Initiatives
  • 11.3.4. Rentschler Biotechnologies GmbH
    • 11.3.4.1. Participant's Overview
    • 11.3.4.2. Financial Performance
    • 11.3.4.3. Service Benchmarking
    • 11.3.4.4. Strategic Initiatives
  • 11.3.5. JRS PHARMA
    • 11.3.5.1. Participant's Overview
    • 11.3.5.2. Financial Performance
    • 11.3.5.3. Service Benchmarking
    • 11.3.5.4. Strategic Initiatives
  • 11.3.6. AGC Biologics
    • 11.3.6.1. Participant's Overview
    • 11.3.6.2. Financial Performance
    • 11.3.6.3. Service Benchmarking
    • 11.3.6.4. Strategic Initiatives
  • 11.3.7. ProBioGen
    • 11.3.7.1. Participant's Overview
    • 11.3.7.2. Financial Performance
    • 11.3.7.3. Service Benchmarking
    • 11.3.7.4. Strategic Initiatives
  • 11.3.8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
    • 11.3.8.1. Participant's Overview
    • 11.3.8.2. Financial Performance
    • 11.3.8.3. Service Benchmarking
    • 11.3.8.4. Strategic Initiatives
  • 11.3.9. Toyobo Co. Ltd.
    • 11.3.9.1. Participant's Overview
    • 11.3.9.2. Financial Performance
    • 11.3.9.3. Service Benchmarking
    • 11.3.9.4. Strategic Initiatives
  • 11.3.10. Samsung Biologics
    • 11.3.10.1.1. Participant's Overview
    • 11.3.10.2. Financial Performance
    • 11.3.10.3. Service Benchmarking
    • 11.3.10.4. Strategic Initiatives
  • 11.3.11. Thermo Fisher Scientific, Inc.
    • 11.3.11.1. Participant's Overview
    • 11.3.11.2. Financial Performance
    • 11.3.11.3. Service Benchmarking
    • 11.3.11.4. Strategic Initiatives
  • 11.3.12. Binex Co., Ltd.
    • 11.3.12.1. Participant's Overview
    • 11.3.12.2. Financial Performance
    • 11.3.12.3. Service Benchmarking
    • 11.3.12.4. Strategic Initiatives
  • 11.3.13. WuXi Biologics
    • 11.3.13.1. Participant's Overview
    • 11.3.13.2. Financial Performance
    • 11.3.13.3. Service Benchmarking
    • 11.3.13.4. Strategic Initiatives
  • 11.3.14. AbbVie, Inc.
    • 11.3.14.1. Participant's Overview
    • 11.3.14.2. Financial Performance
    • 11.3.14.3. Service Benchmarking
    • 11.3.14.4. Strategic Initiatives
  • 11.3.15. ADMA Biologics, Inc.
    • 11.3.15.1. Participant's Overview
    • 11.3.15.2. Financial Performance
    • 11.3.15.3. Service Benchmarking
    • 11.3.15.4. Strategic Initiatives
  • 11.3.16. Catalent, Inc
    • 11.3.16.1. Participant's Overview
    • 11.3.16.2. Financial Performance
    • 11.3.16.3. Service Benchmarking
    • 11.3.16.4. Strategic Initiatives
  • 11.3.17. Cambrex Corporation
    • 11.3.17.1. Participant's Overview
    • 11.3.17.2. Financial Performance
    • 11.3.17.3. Service Benchmarking
    • 11.3.17.4. Strategic Initiatives
  • 11.3.18. Pfizer Inc.
    • 11.3.18.1. Participant's Overview
    • 11.3.18.2. Financial Performance
    • 11.3.18.3. Service Benchmarking
    • 11.3.18.4. Strategic Initiatives
  • 11.3.19. Siegfried Holding AG
    • 11.3.19.1. Participant's Overview
    • 11.3.19.2. Financial Performance
    • 11.3.19.3. Service Benchmarking
    • 11.3.19.4. Strategic Initiatives